Introduction
Positron emission tomography in combination with computer tomography (PET/CT) is a very important method of imaging patients with lymphomas. It is used to define the initial grade of the disease and to assess early response to treatment and after chemotherapy. 1, 2 The most commonly used radiopharmaceutical is 2-deoxy-2-( 18 F) fluorine-D-glucose ( 18 F-FDG). It is taken up in all metabolically active tissues, which are distinguished by increased uptake of glucose. After the transport of 18 F-FDG to a cell, phosphorylation to glucose-6-phosphorate occurs and 18 F-FDG gathers in the cellular cytoplasm without undergoing further reactions. Malignant cells show increased FDG uptake, especially those proliferating fast. 2 Because of this, PET/CT examination is particularly useful in patients with aggressive lymphomas with a high proliferation rate, such as diffuse large B-cell lymphoma (DLBCL). 3 An undoubted shortcoming of 18 F-FDG is that it is not only taken up by malignant cells. Increased glucose metabolism also appears in the course of inflammatory or infectious lesions, which can lead to false-positive results. This of particular clinical importance in the assessment of a patients' response to treatment in both the early assessment and after chemotherapy. In the case of a false-positive PET/CT examination result, a patient can be unnecessarily qualified for treatment intensification. 4, 5 In light of this, other radioactive tracers are being sought which can reduce the risk of false-positive results. Test results have indicated that ( 18 F)-fluoro-3'-deoxy-3'-Lfluorothymidine ( 18 F-FLT) may be a more specific tracer. It is transported to the cells and, as a result of a reaction with thymidine kinase type 1 (TK1), it undergoes phosphorylation to monophosphate and is used in DNA synthesis. This makes 18 F-FLT a good cell proliferation tracer, in contrast with 18 F-FDG, which reflects only increased glucose uptake. [6] [7] [8] There is not much clinical data concerning the use of 18 F-FLT in PET/CT imaging of lymphomas.
The aim of our study was to compare the staging of DLBCL with PET/CT examination using 18 F-FLT and 18 F-FDG.
Material and methods
The study included 33 patients with newly diagnosed DLBCL (17 women and 16 men). The median age of the examined group was 57 years (range: 20-74 years). Nine patients (27%) were at stage I according to Ann Arbor staging; 13 patients (40%) were at stage II; 6 (18%) were at stage III; and 5 (15%) at stage IV. In 10 patients a bulky mass tumor (>7 cm) was found. Two PET/CT scans were performed on each patient before treatment: one of them using 18 F-FLT and the other with 18 F-FDG. The interval between PET/CT scans did not exceed 7 days. Each patient gave written consent to take part in this study. The study protocol was approved by the Wroclaw Medical University Bioethics Commission.
The patients' clinical data is presented in Table 1 .
PET-FDG and PET-FLT examinations
PET/CT examinations using 18 F-FDG were performed in patients who had fasted for 6 h; the concentration of glucose in the blood serum was under 150 mg/dL. Imaging from the cranial base to the upper third of the thighs was performed using Biograph 6 and Biograph mCT scanners (Siemens AG, Munich, Germany) 60 ±10 min after injecting FDG intravenously in doses of 5-7 MBq/kg of body mass. The procedure for the PET/CT using 18 F-FLT was the same: The patients had not eaten for at least 6 h; imaging was performed with Biograph 6 and Biograph mCT scanners 60 ±10 min after administering 350 MBq/kg of FLT. Whole-body CT scanning was used for attenuation correction and anatomical localization. Standard CT scans were undertaken at 120 kV, 100 mAs, 0.8 s rotation with a 1.25-mm slice width, and with no contrast injection. Image interpretation was performed using the Syngovia application and the MI Oncology workstation (Siemens AG).
PET/CT examination assessment
To ensure proper interpretation, nuclear medicine and radiology specialists read the scans. Any discrepancies in interpretation were resolved by consensus. The tumors were localized according to the CT scans. Increased focal uptake was detected in the tumor and assessed by measuring the maximum standardized uptake value (SUV max ). Ellipsoidal volumes of interest (VOIs) with the diameter of the particular lesion were placed in the chosen areas of the highest uptake affected by lymphomas. The SUV max from these VOIs was calculated according to the standard formula (Bq/g × body weight [g]/ injected activity in Bq). FLT uptake was compared with FDG uptake for a particular lesion (lesion-to-lesion analysis). Next, the mean SUV values of individual patients were calculated to eliminate any influence connected with the number of lesions in particular patients. The mean SUV max values for FLT and FDG in individual patients were compared (patientto-patient analysis).
The results were analyzed statistically using STATIS-TICA v. 8.0 software (StatSoft Inc., Tulsa, USA). The statistical analysis was included the Mann-Whitney U test, Student's t-test, and Pearson and Spearman correlation methods. Differences were considered statistically significant at the p < 0.05 level.
Results
The first PET examination performed on all the patients was the scan using 18 F-FLT, followed by the one using 18 F-FDG. The time between tests was from 2 to 7 days. In the whole examined group, a total of 450 avid lesions were revealed. The 18 F-FLT PET scan found 28 lesions in 3 patients that were not avid during the test using 18 F-FDG. In the 18 F-FDG PET examination, 17 lesions were found in 7 patients that were invisible in the 18 F-FLT PET exam. The differences between the lesions discovered with the use of 18 F-FDG and 18 F-FLT did not entail any changes in the assessments of the degree of disease progression.
The correlation between FLT and FDG activity
The average SUV max of F-FDG uptake in the whole group of patients was 11.56 (median 8.6), which was significantly higher than the value of the average SUV max of F-FLT uptake, which was 8.62 (median 8.4). There was a statistically significant correlation between the F-FDG and F-FLT uptake values (Pearson product-moment correlation coefficient = 0.37). The results are presented in Fig. 1 and Fig. 2 .
Comparison of FDG and FLT uptakes in particular patients
Comparing the average maximum FLT and FDG uptakes between particular patients, it turned out that they were significantly higher in the FDG PET examination than in the FLT PET scan (14.908 vs 7.73) (p < 0.05).
Individual FLT uptake
In 3 patients, the average FLT value was significantly higher (p = 0.029) than in other patients. Also, the initial SUV max of FLT in these 3 patients was clearly higher than their FDG SUV max (7.84 ±3.36 vs 5.6 ±4.67). In all 3 patients with an increased FLT uptake, the disease course was more aggressive than in the rest of the participants. These patients died during treatment. Our results may point to a relationship between intensified F-FLT uptake and a poor clinical course of the disease.
Correlations between FDG and FLT SUV values and selected factors
In the entire patient population, an analysis was performed of correlations between FDG and FLT activity and D-lactate dehydrogenase (D-LDH) activity, beta-2 microglobulin concentration, International Prognostic Index (IPI) value, and the value of the proliferation marker Ki-67. We found a statistically significant positive correlation between FDG and FLT activity. A positive correlation was also found between FLT and D-LDH activity, although that connection was not statistically significant.
The results are presented in Table 2 .
FLT activity in relation to gender
The tests found a statistically significant difference between the FLT uptake value in women and in men: FLT uptake was higher in women than in men (p = 0.0011).
FDG and FLT activity in the assessment of bone marrow involvement
Each patient in the study population had a bone marrow biopsy performed before the start of chemotherapy. In 2 patients, bone marrow infiltration by lymphoma cells was found in the histopathological examination, although neither the FDG nor the FLT PET exams revealed any bone marrow involvement in either case.
Discussion
PET-CT examination is at present the imaging standard in aggressive non-Hodgkin lymphomas (NHL), both before the start of a therapy and in assessments after the end of treatment. 3 In high-grade NHL like DLBCL, the true negative rate of the PET-CT results is confirmed after the end of chemotherapy. 9 18 F -FDG is a radioactive tracer that is commonly used in PET-CT examinations, but due to the non-specificity of FDG uptake, compounds that could decrease the probability of false-positive results are being sought. 18 F-FLT, which was used for the first time by Shields et al., seems to be such a radioactive tracer. 10 That study showed that 18 F-FLT PET results correlate with the cell proliferation degree in solid neoplasms and in lymphomas. 5, 11, 12 In a group of 20 patients with small cell lung cancer, Everitt et al. conducted 18 F-FLT PET and 18 F-FDG PET scans before the start of treatment and during therapy. It turned out that 18 F-FLT PET was more sensitive test than 18 F-FDG PET. 13 In a study of 20 patients with breast cancer, 18 F-FLT PET was performed before the start of the treatment and before the second chemotherapy cycle. 14 The SUV max 18 F-FLT PET value before the treatment significantly correlated with Ki-67 activity, which suggested the role of FLT in defining neoplasm proliferation activity. After the end of chemotherapy a significant decrease in the 18 F-FLT PET SUV max value was observed in connection with the reduction of the tumor mass. 14 Cho et al. conducted an study using 18 F-FLT PET and 18 F-FDG PET scans in patients with cervical and vaginal cancer before therapy and after the end of chemo-and radiotherapy. 15 The FLT SUV max value was significantly lower than the FDG SUV max in the first examination. After treatment, the FLT SUV max value was much lower regardless of the presence of the inflammatory response after radiotherapy. The study results point to the possibility of monitoring gynecological neoplasm treatment results with 18 F-FLT PET.
The use of 18 F-FLT PET in imaging lymphoid tumors is not a diagnostic standard and there are very few data concerning the use of this method in this group of patients. Lee et al. assessed the role of early 18 F-FLT PET scans as a prognostic index in a group of 61 patients with NHL. 16 The population examined included patients with DLBCL, mantle cell lymphoma (MCL), follicular lymphoma (FL), Burkitt lymphoma, natural killer cell lymphoma, and T-cell lymphoma. 18 F-FLT PET scans were performed before the treatment, after the first chemotherapy cycle and after the treatment. The patients with a positive result in the early 18 F-FLT PET examination had shorter progression-free survival (PFS) and shorter overall survival (OS) in comparison to the patients with negative PET results (PFS 52% vs 80.7% and OS 56.2% vs 81.4%). 16 In a group of 17 patients with FL and FL transformation, Wondergem et al. compared the SUV max values for 18 F-FLT PET and 18 F-FDG PET. In patients with FL transformation, the SUV max values for both 18 F-FLT and 18 F-FDG were significantly higher than in the group of patients with FL without transformation. In the population with FL transformation, 18 F-FDG PET revealed higher SUV max values than 18 F-FLT PET, and the authors of the study therefore suggested that imaging with 18 F-FDG PET is a better diagnostic option in cases of FL transformation. 17 In the group of 33 untreated DLBCL patients in our study, we compared 18 F-FLT PET and 18 F-FDG PET examinations. In the whole population and also in individual patients, SUV max values for 18 F-FDG were higher than for 18 F-FLT. In 3 patients with an especially aggressive disease course, 28 avid lesions were found in the 18 F-FLT PET examinations that were not visible in the 18 F-FDG PET examination. The SUV max values for 18 F-FLT PET in those patients were significantly higher than their 18 F-FDG PET SUV values. These results suggest that 18 F-FLT PET-CT can be used as an indicator of an aggressive clinical course in patients with DLBCL. In the population we assessed, the 18 F-FLT PET examinations were conducted before the start of therapy. Herrmann et al. conducted 18 F-FLT PET scans in patients with DLBCL before the treatment and a week after the first chemotherapy cycle (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone). 18 The reduction of SUV max values for 18 F-FLT after the first chemotherapy cycle was significantly higher in patients who achieved complete remission after chemotherapy. It seems that early 18 F-FLT PET examinations can be useful in assessing the efficacy of treatment. 18 In aggressive NHLs such as DLBCL, a negative PET test result has a confirmed predictive value after the end of treatment. However, early 18 F-FDG PET scans can carry a risk of false-positive results in connection with the immunochemotherapy used, which can lead to reactive changes caused by treatment itself.
We also noticed that in our study group 18 F-FLT values were significantly higher in the females than in the males. This observation requires further analysis in a larger patient population.
Conclusions
The results of our study suggest that 18 F-FLT PET-CT can be a useful diagnostic method in the assessment of patients with DLBCL. Data from the available literature also indicates this. Our analysis concerned a small group of patients and the results are preliminary, requiring confirmation in a larger population of patients.
